Why KalVista Pharmaceuticals Stock Skyrocketed 115% Today
1 minuto de lectura
What happenedShares of KalVista Pharmaceuticals (NASDAQ: KALV) soared 115% on Tuesday after the pharmaceutical company released promising results from its phase 2 clinical trial for KVD900, its oral drug for hereditary angioedema (HAE) attacks.Read MoreMarketsMarkets Feed
Descubre más desde Espacioteca
Suscríbete y recibe las últimas entradas en tu correo electrónico.
